TVB-2640 for Carcinoma, Non-Small-Cell Lung

Carcinoma, non-small-cell lung is a highly aggressive cancer, and its overall prognosis is poor. Due to these factors, it is necessary to assess the current status of treatment for patients with carcinoma, non-small-cell lung with regard to PFS. This is a crucial point for developing an effective treatment strategy. In this paper, standard therapeutic options for carcinoma, non-small-cell lung and strategies to improve treatment for patients with carcinoma, non-small-cell lung was reviewed, and the treatment options for carcinoma, non-small-cell lung were organized according to PFS.

Carcinoma, non-small-cell lung make up 5.8% of Americans. Carcinoma, non-small-cell lung comprise 1.9% of all malignancies reported to the Centers for Disease Control and Prevention in the United States in 2000. The most common cancer in 2000 was small cell carcinoma, malignant neuroblastoma of the lung, (14.7% of all reported malignancies); the second most common was squamous cell carcinoma, non-small cell lung (11.5% of all reported malignancies) and adenoid cystic carcinoma of the salivary gland, (8.2% of all reported malignancies).

Carcinoma, non-small-cell lung, first appeared in the third millennium, about 4000 years later than what was previously hypothesized. A combination of radiometric and genetic evidence strongly supports a relationship between this tumour and smoking.

It is very difficult to predict whether a carcinoma, NSCLC can be cured, or not. However, it is possible to cure it if it is detected early and treated.

Patients with cancer of the lung with a palpable mass and persistent or worsening symptoms of cough should undergo CT scan. Imaging is particularly helpful in detecting unsuspected metastases or unsuspected pneumonic disease.

The cause of carcinoma is still unknown; however, it almost certainly is multifactorial. Tobacco smoking appears to play a causative role, as does occupational asbestos exposure.

TVB-2640 is a novel synthetic compound. Its chemical structure and mode of action are similar to cyclophosphamide. Despite the structural similarity, this compound causes very different anticancer activity.

A combination treatment with a low-dose combination of TVB-2640 with a second-line treatment was effective and safe in this study. In view of the limited number of patients and their inclusion criteria, the results need to be confirmed in a larger study.

To date, this medication has not been proven to be more effective than a placebo. Moreover, for patients who already received a bronchodilator, the side-effects of this medication were more problematic than their adverse drug reactions in general.

In people with carcinoma, non-small-cell lung, in whom the cancer is growing and invading surrounding tissues, the TV-2640 combination improved both quality of life and survival by slowing the tumor growth rate and reducing symptoms of cough and dyspnea.

TVB2640 was efficacious and safe as a single agent and combination therapy in early-phase clinical trials. Further studies, preferably randomized phase III trials, are warranted to assess its utility in the treatment-resistant setting. Clin Cancer Res; 1-10. ©2016 AACR.